Literature DB >> 32005431

Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer.

Roberto Ruiz-Cordero1, Walter Patrick Devine2.   

Abstract

Lung cancer is the leading cause of cancer mortality. It is classified into different histologic subtypes, including adenocarcinoma, squamous carcinoma, and large cell carcinoma (commonly referred as non-small cell lung cancer) and small cell lung cancer. Comprehensive molecular characterization of lung cancer has expanded our understanding of the cellular origins and molecular pathways affected in each of these subtypes. Many of these genetic alterations represent potential therapeutic targets for which drugs are constantly under development. This article discusses the molecular characteristics of the main lung cancer subtypes and discusses the current guidelines and novel targeted therapies, including checkpoint immunotherapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Checkpoint inhibitors; Immunotherapy; Lung cancer; Molecular landscape; Non–small cell lung cancer; Resistance mechanisms; Targeted therapy

Mesh:

Year:  2020        PMID: 32005431     DOI: 10.1016/j.path.2019.11.002

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  67 in total

1.  Sauchinone: a prospective therapeutic agent-mediated EIF4EBP1 down-regulation suppresses proliferation, invasion and migration of lung adenocarcinoma cells.

Authors:  Sheng-Qian Li; Jing Feng; Ming Yang; Xiao-Peng Ai; Mei He; Fu Liu
Journal:  J Nat Med       Date:  2020-07-15       Impact factor: 2.343

2.  Physicochemical Characterization and Biopharmaceutical Evaluation of ZWF: A Novel Anticancer Drug for the Treatment of Non-small Cell Lung Cancer.

Authors:  Lina Zhao; Li He; Yuan Chen; Tongchao Xia; Le Li; Shengyan Wang; Xu Bao; Junyi Yang
Journal:  AAPS PharmSciTech       Date:  2021-07-23       Impact factor: 3.246

Review 3.  Roles of circular RNAs in regulating the development of glioma.

Authors:  Jianing Fan; Yangyang Wang; Xiao Liang; Fanlin Zhou; Shijie Li; Xiaoju Li; Yu Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-01       Impact factor: 4.553

4.  Diagnostic and prognostic value of CT perfusion parameters in patients with advanced NSCLC after chemotherapy.

Authors:  Guangyao Lin; Yuan Sui; Yiming Li; Wenqi Huang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

5.  NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.

Authors:  Deepanwita Sengupta; Liyong Zeng; Yumei Li; Simone Hausmann; Debopam Ghosh; Gang Yuan; Thuyen N Nguyen; Ruitu Lyu; Marcello Caporicci; Ana Morales Benitez; Garry L Coles; Vladlena Kharchenko; Iwona Czaban; Dulat Azhibek; Wolfgang Fischle; Mariusz Jaremko; Ignacio I Wistuba; Julien Sage; Łukasz Jaremko; Wei Li; Pawel K Mazur; Or Gozani
Journal:  Mol Cell       Date:  2021-09-22       Impact factor: 17.970

6.  Tumor Cells Modulate Macrophage Phenotype in a Novel In Vitro Co-Culture Model of the NSCLC Tumor Microenvironment.

Authors:  Josiah Voth Park; Raghav Chandra; Ling Cai; Debolina Ganguly; Huiyu Li; Jason E Toombs; Luc Girard; Rolf A Brekken; John D Minna
Journal:  J Thorac Oncol       Date:  2022-07-05       Impact factor: 20.121

7.  UBE2L3 promotes lung adenocarcinoma invasion and metastasis through the GSK-3β/Snail signaling pathway.

Authors:  Xingjie Ma; Weibo Qi; Fan Yang; Huan Pan
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

8.  Alternol triggers immunogenic cell death via reactive oxygen species generation.

Authors:  Changlin Li; Ying Zhang; Siyuan Yan; Guoan Zhang; Wei Wei; Zhi Qi; Benyi Li
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110

Review 9.  Molecular Testing on Cytology for Gene Fusion Detection.

Authors:  Fernando Schmitt; Alessia Di Lorito; Philippe Vielh
Journal:  Front Med (Lausanne)       Date:  2021-07-06

10.  The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.

Authors:  Yicheng Liang; Yangyang Lei; Minjun Du; Mei Liang; Zixu Liu; Xingkai Li; Yushun Gao
Journal:  J Cell Mol Med       Date:  2021-06-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.